Why the study?
The mechanisms by which hyperglycemia disturbs retinal capillary homeostasis in early diabetic retinopathy are poorly understood, hindering the development of effective early treatments.
LRG1 drives early vascular dysfunction in diabetic retinopathy and represents a potential preemptive therapeutic target.
LRG1 inhibition may offer early intervention in diabetic retinopathy models; leaves open clinical translation pending human studies.
Diabetic retinopathy (DR) is a common complication of diabetes mellitus and a leading cause of visual impairment and blindness in the working-age population. The early stage of the disease is characterized by retinal capillary dysfunction, but the mechanisms whereby hyperglycemia disturbs capillary homeostasis at this initiating stage are poorly understood, posing a barrier to the development of effective early treatments. We used two mouse models of type I diabetes that replicate early features of human retinal vascular pathology. In both the streptozotocin (STZ) model, where hypoinsulinemia is chemically induced, and in the Ins2Akita model, which develops it spontaneously because of a mutation in the insulin gene, we observed early induction of the secreted glycoprotein gene leucine-rich α-2-glycoprotein 1 ( Lrg1 ). Using the Ins2Akita mice, we showed that Lrg1 induction preceded that of vascular endothelial growth factor A ( Vegfa ). LRG1 initiated retinal microvascular dysfunction by modifying transforming growth factor–β (TGFβ) signaling in pericytes, driving transdifferentiation to a more contractile fibrotic phenotype, resulting in narrower capillaries and thickened basement membrane. Using computational modeling, we showed that these early vascular changes impaired retinal blood flow and oxygen delivery, consistent with a defect in visual transduction observed in both models. This early retinal phenotype could be rescued by Lrg1 knockout or by treatment with an LRG1 function–blocking antibody in both the STZ and Ins2Akita mice. These results demonstrate that LRG1 is a driver of vascular dysfunction that contributes to the onset of DR and presents itself as a potential preemptive therapeutic target.
No takes yet. Share an insight, caveat, or question.
Rossi et al. (2025) studied Diabetic retinopathy. Lrg1 knockout or LRG1 function-blocking antibody was evaluated on Rescue of early retinal phenotype (microvascular dysfunction and visual transduction defect).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: